Literature DB >> 31522370

Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.

Naoya Toriu1, Naoki Sawa2, Rikako Hiramatsu2, Hiroki Mizuno2, Daisuke Ikuma2, Akinari Sekine2, Noriko Hayami2, Keiichi Sumida2, Masayuki Yamanouchi2, Eiko Hasegawa2, Junichi Hoshino2, Kenmei Takaichi2,3, Atsushi Wake4, Kenichi Ohashi5,6, Takeshi Fujii4, Yoshifumi Ubara2,3.   

Abstract

We report a 58-year-old Japanese woman who presented with nephrotic syndrome. Steroid therapy and cyclosporine A administration were initiated, but hematological remission and renal response were not achieved. Renal biopsy revealed amyloid deposits in the mesangial region and the small arteries. Proteomic analysis based on laser microdissection and mass spectrometry showed that the amyloid deposits were composed of the constant region of the lambda light chain. She received vincristine, adriamycin, and dexamethasone therapy followed by high-dose melphalan and autologous stem cell transplantation, resulting in hematological complete remission and renal response with negative urinary Bence-Jones protein and proteinuria. Renal biopsy was performed four times during follow-up, demonstrating that amyloid deposits decreased gradually, while glomeruli showing global sclerosis increased from 3 to 62%. This case suggests that glomerular amyloid deposits can be cleared via tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated cells after stem cell transplantation.

Entities:  

Keywords:  AL amyloidosis; Autologous stem cell transplantation; High-dose melphalan; Vincristine; adriamycin; and dexamethasone

Mesh:

Substances:

Year:  2019        PMID: 31522370      PMCID: PMC6990336          DOI: 10.1007/s13730-019-00416-1

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  18 in total

Review 1.  Amyloidosis and the respiratory tract.

Authors:  J D Gillmore; P N Hawkins
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

2.  Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies.

Authors:  Nagaaki Katoh; Masayuki Matsuda; Ayako Tsuchiya-Suzuki; Shu-ichi Ikeda
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

3.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Resolution of primary amyloidosis by melphalan and prednisolone: a case report.

Authors:  M Nakayama; M Kashiwagi; R Katafuchi; K Hori; S Hayashi; S Fujimi
Journal:  Clin Nephrol       Date:  2005-03       Impact factor: 0.975

5.  Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.

Authors:  Takahisa Gono; Masayuki Matsuda; Naoko Dohi; Kenichi Hoshi; Tsuyoshi Tada; Kazuo Sakashita; Kenichi Koike; Masatsugu Aizawa; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2003-01       Impact factor: 1.271

6.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

7.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

Review 8.  Novel Therapies in Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Kidney Int Rep       Date:  2017-11-28

Review 9.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

10.  Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Daisuke Kobayashi; Yoko Wada; Shuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  BMC Nephrol       Date:  2012-09-24       Impact factor: 2.388

View more
  2 in total

1.  Kidney biopsy guidebook 2020 in Japan.

Authors:  Yoshifumi Ubara; Takehiko Kawaguchi; Tasuku Nagasawa; Kenichiro Miura; Takayuki Katsuno; Takashi Morikawa; Eiji Ishikawa; Masao Ogura; Hideki Matsumura; Ryota Kurayama; Shinsuke Matsumoto; Yuhji Marui; Shigeo Hara; Shoichi Maruyama; Ichiei Narita; Hirokazu Okada; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2021-04       Impact factor: 2.801

Review 2.  Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review.

Authors:  Ping Zhang; Xiuling Chen; Yurong Zou; Wei Wang; Yunlin Feng
Journal:  BMC Nephrol       Date:  2022-03-31       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.